论文部分内容阅读
用小剂量干扰素诱导剂>PolyI:C及免疫刺激剂刺五加配伍,治疗慢性乙肝感染者32例(慢迁肝12例,无症状HBsAg携带者20例),同时以26例(慢迁肝11例,无症状HBsAg携带者15例)作为治疗对照。三个月后,治疗组病例血清HBsAg滴度显著下降,而对照组则反见滴度上升,两组比较HBsAg滴度下降率分别为59.38％及7.69％(P<0.0001)。治疗组无滴度上升者,对照组有30.77％的病例滴度上升(P<0.001)。此外,治疗组肝功能絮状试验有明显好转,与对照组有显著差异(p<0.05)。血清中的HBsAg滴度降低,可能间接反映出降低了的病人及携带者的传染性,值得进一步研究提高其疗效。
With low-dose interferon inducer> PolyI: C and immunostimulant Acanthopanax compatibility, the treatment of chronic hepatitis B infection in 32 patients (12 cases of slow-moving liver, asymptomatic HBsAg carriers in 20 cases), while 26 cases 11 cases of liver, asymptomatic HBsAg carriers in 15 cases) as a control. Three months later, the serum HBsAg titer in the treatment group decreased significantly, while the control group showed an inverse titer increase. The reduction rates of HBsAg titer in the two groups were 59.38% and 7.69%, respectively (P <0.0001). In the untreated group, the titers of the control group increased by 30.77% (P <0.001). In addition, the treatment group, liver function flocculation test was significantly improved, and the control group were significantly different (p <0.05). The decrease of HBsAg titer in serum may indirectly reflect the reduced contagiousness of patients and carriers, which is worth further study to improve its curative effect.